If you have been reading about peptide hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
oxidative phosphorylation Also electron transport-linked phosphorylation or terminal oxidation. The process by which cells use chemical energy obtained by the oxidation of nutrients to power the production of adenosine triphosphate (ATP). Oxidative phosphorylation couples two related processes: in the electron transport chain, a series of enzyme-catalyzed redox reactions transfers electrons from energetic donors such as NADH and FADH through various intermediates and ultimately to a terminal electron acceptor such as molecular oxygen (O2); the energy liberated by these reactions is simultaneously used in chemiosmosis to move protons (H+) across a membrane and against their concentration gradient, generating an electrochemical potential which powers ATP synthase, an enzyme that catalyzes the phosphorylation of ADP into ATP. In eukaryotes, both of these processes are carried out by proteins embedded in the membranes of mitochondria and chloroplasts; in prokaryotes, they occur in the cell membrane.
=== Phytoestrogens === Isoflavones, which are structurally related to 17β-estradiol, are classified as phytoestrogens. A risk assessment by the European Food Safety Authority found no cause for concern when isoflavones are consumed in a normal diet.
=== Catalysis === Enzyme specificity refers to the interactions between any particular enzyme and its corresponding substrate. In addition to the specificity in binding its substrates, correct proximity and orientation as well as binding the transition state provide an additional layer of enzyme specificity.
== Products and services == Repligen develops and manufactures products used in bioprocessing and biological drug manufacturing. The company was a major supplier of Protein A, both native and recombinant forms, to the pharmaceutical industry, which accounted for most of its sales in the early 2010s. It has since expanded into other areas, including filtration and fluid management, chromatography, process analytics and proteins, serving biologics such as monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, mRNA products, and cell and gene therapies. Some of its better-known product families include XCell ATF perfusion systems, OPUS pre-packed chromatography columns, KrosFlo tangential flow filtration systems, and CTech variable pathlength spectroscopy systems such as SoloVPE and FlowVPE. Many of these expansions have occurred through acquisitions, including BioFlash (OPUS), Refine Technology (ATF), ARTeSYN Biosolutions, and others. Growth factor products and the native form of Protein A and recombinant Protein A are manufactured in Sweden; assembly of the OPUS chromatography product line is done in the United States.
Dithiocarbamate fungicides are also associated with increased PD risk. Organochlorine pesticides such as DDT were banned in the United States in 1972; pesticides such as dieldrin are also associated with increased PD risk and still may be used elsewhere. Organophosphates such as chlorpyrifos and diazinon are linked with increased PD risk, and have been banned in the European Union. Concerns have been raised about pyrethroid pesticides such as cypermethrin, which are globally used both agriculturally and domestically, often as a replacement for organophosphates. Rural living, well-drinking, and farming are all associated with Parkinson's, which may be partly explained by local pesticide exposure through direct contact and contaminated air or ground water. These factors are pertinent to many communities, including Brazilian and South Asian populations. Organochlorine pesticides continue to be associated with increased risk for Parkinson's disease in Asia. In France, Parkinson's disease was officially recognized as an occupational disease of agricultural workers in 2012. A Decree acknowledging a causal link between pesticides and PD entered into force on 7 May 2013. In March 2024, Germany formally adopted a similar recommendation for the occupational disease category of "Parkinson's Disease caused by pesticides", no longer using the term "idiopathic" PD. Since 2019, the Movement Disorder Society (MDS) has included "regular pesticide exposure" as a risk factor in the MDS research criteria for prodromal Parkinson's disease. Many pesticides are mitochondrial toxins.
Sources: en.wikipedia.org
Dextranomer (trade name Debrisan, Exudex) is a cicatrizant used in dressings for wound healing, and in pharmaceutical products to treat fecal incontinence. It consists of dextran polymer chains cross-linked into a three-dimensional network.
The two substrates of this enzyme are D-glyceric acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 2-hydroxy-3-oxopropanoate, reduced NADH, and a proton. The enzyme can alternatively use nicotinamide adenine dinucleotide phosphate as its cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (R)-glycerate:NAD(P)+ oxidoreductase. This enzyme is also called tartronate semialdehyde reductase. This enzyme participates in glyoxylate and dicarboxylate metabolism.
The history of smallpox extends into pre-history. Genetic evidence suggests that the smallpox virus emerged 3,000 to 4,000 years ago. Prior to that, similar ancestral viruses circulated, but possibly only in other mammals, and possibly with different symptoms. Only a few written reports dating from about 500–1000 CE are considered reliable historical descriptions of smallpox, so understanding of the disease prior to that has relied on genetics and archaeology. However, during the second millennium, especially starting in the 16th century, reliable written reports become more common. The earliest physical evidence of smallpox is found in the Egyptian mummies of people who died some 3,000 years ago. Smallpox has had a major impact on world history, not least because indigenous populations of regions where smallpox was non-native, such as the Americas and Australia, were rapidly and greatly reduced by smallpox (along with other introduced diseases) during periods of initial foreign contact, which helped pave the way for conquest and colonization. During the 18th century, the disease killed an estimated 400,000 Europeans each year, including five reigning monarchs, and was responsible for a third of all blindness. Between 20 and 60% of all those infected—and over 80% of infected children—died from the disease. During the 20th century, it is estimated that smallpox was responsible for 250–500 million deaths. In the early 1950s, an estimated 50 million cases of smallpox occurred in the world each year.
=== Isomerisation === In dilute sodium hydroxide or other dilute bases, the monosaccharides mannose, glucose, and fructose interconvert (via a Lobry de Bruyn–Alberda–Van Ekenstein transformation), so that a balance between these isomers is formed. This reaction proceeds via an enediol:
Sources: en.wikipedia.org
=== 11 July === Eight people were killed by an SAF airstrike in Abu Zabad, West Kordofan. The RSF launched a major attack on El Fasher, seizing the city's main livestock market, the Shalla prison and the headquarters of the Central Reserve Forces before being driven back the next day by the SAF.
Electrotaxis, also known as galvanotaxis (named after Galvani), is the directed motion of biological cells or organisms guided by an electric field or current. The directed motion of electrotaxis can take many forms, such as; growth, development, active swimming, and passive migration. A wide variety of biological cells can naturally sense and follow DC electric fields. Such electric fields arise naturally in biological tissues during development and healing. These and other observations have led to research into how applied electric fields can impact wound healing An increase in wound healing rate is regularly observed and this is thought to be due to the cell migration and other signaling pathways that are activated by the electric field. Additional research has been conducted into how applied electric fields impact cancer metastasis, morphogenesis, neuron guidance, motility of pathogenic bacteria, biofilm formation, and many other biological phenomena.
The condensation of N-(2-fluoro-6-(trifluoromethyl)benzyl)urea [830346-46-8] (1) with t-butyl acetoacetate [1694-31-1] under acidic conditions to generate the 6-methyluracil derivative, [830346-47-9] (2). Halogenation using iodine monochloride provided [1150560-54-5] (3). Suzuki coupling with 2-fluoro-3-methoxyphenylboronic acid [352303-67-4] (4) gave [1150560-59-0] (5). The catalyst used for this step was PdCl2(dtbpf). FGI of N-Boc-2-phenyl-D-glycinol [102089-74-7] (6) to the mesylate, [102089-75-8] (7) was followed by alkylation and alkaloine hydrolysis of the Boc protecting group to give [830346-50-4] (8). Alkylation of the primary amine with ethyl 4-bromobutyrate [2969-81-5] (9) gave ester [832720-84-0] (10). Saponification of the ester in alcoholic lye completed the synthesis of elagolix sodium (11).
== Function == This gene encodes one of the three alpha chains of type IX collagen, the major collagen component of hyaline cartilage. Type IX collagen, a heterotrimeric molecule, is usually found in tissues containing type II collagen, a fibrillar collagen. Mutations in this gene are associated with multiple epiphyseal dysplasia.
Ginkgo has long been cultivated in China. It is common in the southern third of the country. Some planted trees at temples are believed to be over 1,500 years old. The first record of Europeans encountering it is in 1690 in Japanese temple gardens, where the tree was seen by the German botanist Engelbert Kaempfer. Because of its status in Buddhism and Confucianism, the ginkgo has also been widely planted in Korea and in Japan since the 14th century; in both areas, some naturalization has occurred, with ginkgos seeding into natural forests. Ginkgo has been commonly cultivated in North America for over 200 years and in Europe for close to 300, but during that time, it has never become significantly naturalized. G. biloba is also commonly manually planted in cities across the United States and Europe. This species is highly tolerant to pollution and serves as a visually appealing, shade-providing tree in many cities and gardens. Many intentionally planted ginkgos are male cultivars grafted onto plants propagated from seed, because the male trees will not produce the malodorous seeds. The popular cultivar 'Autumn Gold' is a clone of a male plant. The disadvantage of male Ginkgo biloba trees is that their pollen is highly allergenic. They have an OPALS (Ogren Plant Allergy Scale) rating of 7 (out of 10), whereas female trees, which can produce no pollen, have an OPALS allergy scale rating of 2.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.